ADC Therapeutics SA (NYSE:ADCT)
$ 3.43 -0.01 (-0.29%) Market Cap: 330.06 Mil Enterprise Value: 220.10 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 45/100

ADC Therapeutics SA at Cantor Fitzgerald Global Healthcare Conference (Virtual) Transcript

Sep 30, 2021 / 01:20PM GMT
Release Date Price: $27.16 (+1.19%)
Brian Cheng
Cantor Fitzgerald, L.P. - Analyst

Good morning. Thank you for joining us today at our annual Global Healthcare Conference. I am Brian Cheng. I'm the Senior Biotech Analyst here at Cantor. It is my pleasure to introduce your next management team from ADC Therapeutics. Joining us is their CEO, Chris Martin.

Chris, welcome, and thank you so much for joining us today.

Chris Martin
ADC Therapeutics SA - CEO, Co-Founder & Director

Pleasure, Brian, and thank you.

Brian Cheng
Cantor Fitzgerald, L.P. - Analyst

Great. So let's start off with a quick presentation from the management team and then we'll transition to our fireside chat.

Chris, the floor is yours.

Chris Martin
ADC Therapeutics SA - CEO, Co-Founder & Director

Thanks, Brian. I will just use a couple of slides to give you a very quick background. So for the normal forward-looking statements -- so we've had, as you know, the recent approval of ZYNLONTA. And that is in the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot